PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
German Hodgkin Study Group HD17 trial investigated whether radiotherapy could be omitted without loss of efficacy in patients with early-stage unfavourable Hodgkin lymphomas. 5-year progression-free survival was 97% in the standard combined-modality treatment group and 95% in PET4-guided treatment group.
